Literature DB >> 1731289

Randomized comparative trial of indomethacin and sulindac for the treatment of refractory preterm labor.

S J Carlan1, W F O'Brien, T D O'Leary, D Mastrogiannis.   

Abstract

This study was designed to investigate the efficacy and safety of sulindac in the treatment of preterm labor. Thirty-six women in preterm labor who had failed initial attempts at tocolysis with magnesium sulfate were randomized to receive either oral indomethacin or oral sulindac for 48 hours. The mean gestational ages at admission were 29 and 30 weeks for the sulindac and indomethacin groups, respectively. There was a significantly greater hourly fetal urine output, deepest amniotic fluid pocket, and amniotic fluid index in the sulindac group. A trend toward higher fetal ductus arteriosus flow velocities noted in the indomethacin group was not seen in the sulindac group. The drugs had similar success in delaying delivery for 48 hours or 7 days. The mean birth weights were 2000 and 2323 g for the sulindac and indomethacin groups, respectively. Sulindac appears to be as effective as indomethacin for refractory preterm labor but with fewer fetal side effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731289

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

Review 1.  Management of preterm labour.

Authors:  S Vause; T Johnston
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

Review 2.  Prenatal pharmacotherapy for fetal anomalies: a 2011 update.

Authors:  Lisa Hui; Diana W Bianchi
Journal:  Prenat Diagn       Date:  2011-06-03       Impact factor: 3.050

Review 3.  Cyclo-oxygenase (COX) inhibitors for treating preterm labour.

Authors:  Hanna E Reinebrant; Cynthia Pileggi-Castro; Carla L T Romero; Rafaela A N Dos Santos; Sailesh Kumar; João Paulo Souza; Vicki Flenady
Journal:  Cochrane Database Syst Rev       Date:  2015-06-05

Review 4.  Effects of maternally administered drugs on the fetal and neonatal kidney.

Authors:  Farid Boubred; Mariella Vendemmia; Patricia Garcia-Meric; Christophe Buffat; Veronique Millet; Umberto Simeoni
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 6.  Hormonal and local regulation of uterine activity during parturition: Part II--The prostaglandin and adrenergic systems.

Authors:  M Maggi; E Baldi; T Susini
Journal:  J Endocrinol Invest       Date:  1994-10       Impact factor: 4.256

Review 7.  Differences in NSAID tolerability profiles. Fact or fiction?

Authors:  K J Skeith; M Wright; P Davis
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 8.  A risk-benefit assessment of therapies for premature labour.

Authors:  K Higby; C R Suiter
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

Review 9.  Suppression of preterm labour. Current concepts.

Authors:  P Johnson
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 10.  Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?

Authors:  M Ostensen; R Ramsey-Goldman
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.